A phase Ib/II study of cancer stem cell inhibitor BBI608 administered with panitumumab in KRAS wild-type (wt) patients (pts) with metastatic colorectal cancer (mCRC) following progression on anti-EGFR therapy.
Year: 2015
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Kristen Keon Ciombor, William Jeffery Edenfield, Joleen Marie Hubbard, Peter J. O'Dwyer, Carlos Becerra, Tim Larson, Alexander I. Spira, Axel Grothey, Divya Manoharan, Wei Li, Youzhi Li, Laura Borodyansky, Chiang Li, Tanios S. Bekaii-Saab
Institutions: The Ohio State University Wexner Medical Center, Prisma Health, Mayo Clinic, Hospital of the University of Pennsylvania, Virginia Cancer Specialists, Boston Biomedical (United States), The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2301630560